Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Co-authors
(67)
Jade Ghosn
7
Francois Raffi (François Raffi)
6
Marie Laure Chaix
6
Christine Rouzioux
6
Philippe Flandre
6
Journals
(7)
ANTIMICROB AGENTS CHEMOTHER
3
J ANTIMICROB CHEMOTHER
2
Bone
1
HIV CLIN TRIALS
1
HIV MED
1
Keywords
(15)
Embed
Subscribe
Academic
Authors
Isabelle Cohen-Codar
Isabelle Cohen-Codar,Pharmacology,Microbiology,Diseases
Edit
Isabelle Cohen-Codar
Publications:
12
|
Citations:
109
Fields:
Pharmacology
,
Microbiology
,
Diseases
View FAQ about top research areas and Fields of study
Collaborated with
67 co-authors
from 2005 to 2011
|
Cited by
510 authors
Cumulative
Annual
Sort by:
Publications
(12)
BibTeX
|
RIS
|
RefWorks
Download
Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies
K. Briot
,
S. Kolta
,
P. Flandre
,
F. Boué
,
P. Ngo Van
,
I. Cohen-Codar
,
M. Norton
,
J. F. Delfraissy
,
C. Roux
Journal:
Bone
, vol. 48, no. 5, pp. 1133-1139, 2011
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
(
Citations: 3
)
J Ghosn
,
P Flandre
,
I Cohen-Codar
,
P-M Girard
,
M-L Chaix
,
F Raffi
,
P Dellamonica
,
P NgoVan
,
M Norton
,
J-F Delfraissy
Journal:
Hiv Medicine - HIV MED
, vol. 11, no. 2, pp. 137-142, 2010
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV1DNA in the MONARK trial
V. Avettand-Fenoel
,
P. Flandre
,
M. L. Chaix
,
J. Ghosn
,
C. Delaugerre
,
F. Raffi
,
P. NgoVan
,
I. Cohen-Codar
,
J. F. Delfraissy
,
C. Rouzioux
Journal:
Journal of Antimicrobial Chemotherapy - J ANTIMICROB CHEMOTHER
, vol. 65, no. 5, pp. 1005-1007, 2010
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
(
Citations: 5
)
Constance Delaugerre
,
Philippe Flandre
,
Marie Laure Chaix
,
Jade Ghosn
,
Francois Raffi
,
P. Dellamonica
,
H. Jaeger
,
D. Shurmann
,
I. Cohen-Codar
,
P. Ngo Van
,
M. Norton
,
A.-M. Taburet
http://academic.research.microsoft.com/io.ashx?type=5&id=11738384&selfId1=23935031&selfId2=0&maxNumber=12&query=
Journal:
Antimicrobial Agents and Chemotherapy - ANTIMICROB AGENTS CHEMOTHER
, vol. 53, no. 7, pp. 2934-2939, 2009
Simplification and First Validation of a Short Battery of Patient Questionnaires for Clinical Management of HIV-Infected Patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire®
(
Citations: 1
)
B. Spire
,
B. Arnould
,
F. Barbier
,
J. Durant
,
J. Gilquin
,
R. Landman
,
S. Carret
,
C. Saussier
,
S. El Kebir
,
I. Cohen-Codar
Journal:
Hiv Clinical Trials - HIV CLIN TRIALS
, vol. 10, no. 4, pp. 215-232, 2009
Sort by:
Citations
(109 times by 94 publications)
Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen
Pedro Cahn
,
Julio Montaner
,
Patrice Junod
,
Patricia Patterson
,
Alejandro Krolewiecki
,
Jaime Andrade-Villanueva
,
Isabel Cassetti
,
Juan Sierra-Madero
,
Arnaldo David Casiró
,
Raul Bortolozzi
,
Sergio Horacio Lupo
,
Nadia Longo
http://academic.research.microsoft.com/io.ashx?type=5&id=57398925&selfId1=23935031&selfId2=0&maxNumber=12&query=
Journal:
PLOS One
, vol. 6, no. 8, 2011
CD4saurus Rex & HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution
Andrea De Maria
,
Andrea Cossarizza
Journal:
Journal of Translational Medicine - J TRANSL MED
, vol. 9, no. 1, pp. 1-7, 2011
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
(
Citations: 19
)
Joseph J Eron
,
Benjamin Young
,
David A Cooper
,
Michael Youle
,
Edwin DeJesus
,
Jaime Andrade-Villanueva
,
Cassy Workman
,
Roberto Zajdenverg
,
Gerd Fätkenheuer
,
Daniel S Berger
,
Princy N Kumar
,
Anthony J Rodgers
http://academic.research.microsoft.com/io.ashx?type=5&id=29271290&selfId1=23935031&selfId2=0&maxNumber=12&query=
Journal:
Lancet
, vol. 375, no. 9712, pp. 396-407, 2010
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
(
Citations: 14
)
Jose R Arribas
,
Andrzej Horban
,
Jan Gerstoft
,
Gerdt Fätkenheuer
,
Mark Nelson
,
Nathan Clumeck
,
Federico Pulido
,
Andrew Hill
,
Yvon van Delft
,
Thomas Stark
,
Christiane Moecklinghoff
Journal:
Aids
, vol. 24, no. 2, pp. 223-230, 2010
Clinical management of HIV1 resistance
(
Citations: 7
)
Roger Paredes
,
Bonaventura Clotet
Journal:
Antiviral Research - ANTIVIR RES
, vol. 85, no. 1, pp. 245-265, 2010
Comments